Hematologic Oncology

The expert panel explores the immunological aspects of chronic GVHD, highlighting challenges in simultaneous management, addressing fibrosis, and emphasizing the importance of early intervention in evolving transplant care practices.

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz distinguish acute from chronic graft-versus-host disease (GVHD), how such distinction has changed over the last decades, and provide an overview of consensus definitions for disease grading.

The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.

Evandro D. Bezerra, MD, discusses real-world outcomes associated with brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.

The FDA has granted fast track designation to SLS009 for use in patients with relapsed or refractory acute myeloid leukemia.

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.

Nicole Lamanna, MD, looks ahead at the future of treatment of B-cell malignancies, highlighting exciting therapeutic developments.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Asciminib demonstrated a favorable safety profile and induced statistically significant and clinically meaningful major molecular response benefits vs standard-of-care TKIs in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.

Andrew Ip, MD, discusses findings from a study on the use of next-generation sequencing of flow cytometry CD markers and machine learning as a replacement to flow cytometry analysis for the diagnosis of hematologic neoplasms.

A discussion about how ensuring continuity of care for patients with AML on maintenance therapy with a focus on how the care team can coordinate to ensure best outcomes.

Catherine E. Lai, MD, MPH, discusses the goals of maintenance therapy, how to manage treatment-related adverse events, and the impact of treatment on patient’s quality of life.

Brian T. Hill, MD, PhD, discusses the final results from a phase 1/2 trial of carfilzomib given with R-CHOP in the frontline setting for patients with non-germinal center diffuse large B-cell lymphoma.

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

A hematologist/oncologist discusses ongoing research on targeted therapy for patients with relapsed/refractory chronic lymphocytic leukemia.

Comprehensive insights on clinical and patient factors that inform treatment selection and sequencing for patients with B-cell malignancies.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Fernando Cabanillas, MD, a mentor and leader in the lymphoma field, is being recognized for his contributions to the hematologic oncology space.

Dedication to his patients and the field of hematology spanning decades has led Stephen J. Forman, MD, to break down barriers for treating patients with leukemia and lymphoma.

A review of recent data regarding maintenance therapy for patients with AML who achieve first remission, including updates from the 2023 ASH Annual meeting.